logo
  

Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity

Biogen Inc. (BIIB) said that the Phase 3 EVOLVE-MS-2 study demonstrated improved patient-assessed gastrointestinal or GI tolerability of Vumerity, a new FDA-approved treatment for relapsing forms of multiple sclerosis or MS, compared to Tecfidera.
Results for the primary endpoint show patients treated with Vumerity self-reported 46 percent fewer days with intensity scores of =2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), compared to Tecfidera.

The EVOLVE-MS-2 results also indicate that compared to TECFIDERA, VUMERITY-treated patients had lower discontinuations due to GI adverse events (AEs) (0.8 percent vs. 4.8 percent).

VUMERITY is now available in the U.S. for relapsing forms of MS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada. Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13.
Follow RTT